
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ALS2 (alsin Rho guanine nucleotide exchange factor ALS2) encodes a guanine nucleotide exchange factor containing ATS1/RCC1-like, RhoGEF, and VPS9 domains. The protein activates the small GTPase RAB5 and localizes with RAB5 on early endosomal compartments. ALS2 therefore contributes to regulation of early endosomal dynamics and membrane trafficking through control of RAB5 activity.
143B is a human osteosarcoma cell line derived indirectly from the HOS osteosarcoma cell line. The cells are deficient in thymidine kinase (TK−) and resistant to bromodeoxyuridine (BUdR). 143B is used as a model for studying osteosarcoma biology, tumor metabolism, and genetic selection systems involving thymidine kinase deficiency.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 3
Reference Transcript: NM_001410975
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?